202 related articles for article (PubMed ID: 35923142)
1. TGFβ signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy.
Xia J; Zhang Q; Luan J; Min P; Zhang H; Chen G; Ji C; Song N
Cell Cycle; 2023 Jan; 22(1):57-72. PubMed ID: 35923142
[TBL] [Abstract][Full Text] [Related]
2. Lack of TGFβ signaling competency predicts immune poor cancer conversion to immune rich and response to checkpoint blockade.
Moore J; Gkantalis J; Guix I; Chou W; Yuen K; Lazar AA; Spitzer M; Combes AJ; Barcellos-Hoff MH
bioRxiv; 2024 May; ():. PubMed ID: 38496519
[TBL] [Abstract][Full Text] [Related]
3. Overcoming TGFβ-mediated immune evasion in cancer.
Tauriello DVF; Sancho E; Batlle E
Nat Rev Cancer; 2022 Jan; 22(1):25-44. PubMed ID: 34671117
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.
Ciardiello D; Elez E; Tabernero J; Seoane J
Ann Oncol; 2020 Oct; 31(10):1336-1349. PubMed ID: 32710930
[TBL] [Abstract][Full Text] [Related]
5. TGFβ and the Tumor Microenvironment in Colorectal Cancer.
Waldner MJ; Neurath MF
Cells; 2023 Apr; 12(8):. PubMed ID: 37190048
[TBL] [Abstract][Full Text] [Related]
6. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
7. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
8. TGFβ Signaling in Photoaging and UV-Induced Skin Cancer.
Ke Y; Wang XJ
J Invest Dermatol; 2021 Apr; 141(4S):1104-1110. PubMed ID: 33358021
[TBL] [Abstract][Full Text] [Related]
9. The radiobiology of TGFβ.
Barcellos-Hoff MH
Semin Cancer Biol; 2022 Nov; 86(Pt 3):857-867. PubMed ID: 35122974
[TBL] [Abstract][Full Text] [Related]
10. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
11. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
Tauriello DVF; Palomo-Ponce S; Stork D; Berenguer-Llergo A; Badia-Ramentol J; Iglesias M; Sevillano M; Ibiza S; Cañellas A; Hernando-Momblona X; Byrom D; Matarin JA; Calon A; Rivas EI; Nebreda AR; Riera A; Attolini CS; Batlle E
Nature; 2018 Feb; 554(7693):538-543. PubMed ID: 29443964
[TBL] [Abstract][Full Text] [Related]
12. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.
Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A
Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
14. The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial.
Metropulos AE; Munshi HG; Principe DR
EBioMedicine; 2022 Dec; 86():104380. PubMed ID: 36455409
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy.
Zhang Z; Chen L; Chen H; Zhao J; Li K; Sun J; Zhou M
EBioMedicine; 2022 Sep; 83():104207. PubMed ID: 35961204
[TBL] [Abstract][Full Text] [Related]
16. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
[TBL] [Abstract][Full Text] [Related]
17. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.
Yi M; Li T; Niu M; Wu Y; Zhao Z; Wu K
Front Immunol; 2022; 13():1061394. PubMed ID: 36601124
[TBL] [Abstract][Full Text] [Related]
18. TGFβ: Signaling Blockade for Cancer Immunotherapy.
Chen SY; Mamai O; Akhurst RJ
Annu Rev Cancer Biol; 2022; 6(1):123-146. PubMed ID: 36382146
[TBL] [Abstract][Full Text] [Related]
19. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
20. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
